All In Biotech

Drug Trial Radar · NCT02262169

DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers

Last checked: Nov 19, 2026Latest source record: Jul 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

32

Actual

Start

Oct 2014

Primary completion

Feb 2019

Study completion Mar 2019

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
First posted
Oct 10, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-arm, prospective, double-blind, double-dummy, randomized-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), or omeprazole at a dose of 40 mg once daily (before morning meal), for an 8-week course of therapy, for the treatment of patients with any non-bleeding peptic ulcers. DLBS2411 is a bioactive fraction of an Indonesian native herbal, Cinnamomum burmanii, locally known as kayu manis have been proven at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its gastro-protective defense mechanism works through the promotion of COX-2 derived prostaglandin (PgE2) synthesis, stimulating gastric-epithelial mucous and bicarbonate secretion; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. Recent study of DLBS2411 in healthy volunteers demonstrated the effective role and safety of DLBS2411 in suppressing intragastric acidity. Having such mechanisms of action, DLBS2411 is hypothesized to benefit in peptic ulcers.

Conditions

  • Non-Bleeding Peptic Ulcers

Interventions

  • OmeprazoleDrug

    2 Omeprazole capsules 20 mg, once daily

  • Placebo caplet of DLBS2411Drug

    1 placebo caplet of DLBS2411, twice daily

  • DLBS2411Drug

    1 DLBS2411 caplet 250 mg, twice daily

  • Placebo capsule of OmeprazoleDrug

    2 placebo capsules of Omeprazole, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endoscopic ulcer healing rateTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Udayana Sanglah General Hospital

    Denpasar, Bali, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.